Just before the Christmas holiday, in a scramble to avoid a partial government shutdown, both houses of Congress approved a $1.7 trillion government spending bill. Earlier that week, the Senate had amended the Consolidated Appropriations Act of 2023 (the “Appropriations Bill”) to, among other things, reintroduce the Modernization of Cosmetics Regulations Act of 2022 (“MOCRA”). … Continue reading MEET THE MODERNIZATION OF COSMETICS REGULATION ACT OF 2022 — It’s Here!
Category: misbranded drugs
FDA RAISES WARNING FLAGS FOR MARKETING OF CBD PRODUCTS
Happy New Year! 2019 was quite the year in many regards. One such area was the significant growth of the CBD marketplace. In response, in the last quarter of the year, the Food & Drug Administration (“FDA”) got busy issuing warning letters and posting consumer notices regarding the safety and use of cannabidiol ("CBD"). For … Continue reading FDA RAISES WARNING FLAGS FOR MARKETING OF CBD PRODUCTS
Unintentional Drug Claims on Cosmetics Not Actionable
Last month, a long running case against Beiersdorf, Inc., makers of Nivea, was dismissed. I would normally prepare a summary myself, but in this case, the first 3 paragraphs of the court's opinion provides a great summary: Five years ago, Ashley Franz purchased a $10 bottle of Nivea's Skin Firming Hydration Body Lotion from a … Continue reading Unintentional Drug Claims on Cosmetics Not Actionable